Sight Sciences' Re-accelerated Engine: TearCare Takes Off as Glaucoma Stabilizes
Q2 2026 revenue grows 20% (best in three years), guidance jumps, and a shrinking cash burn sets the stage for breakeven—while a fresh payer win broadens the runway.
SGHT · Earnings Call · 2026-08-05
There are moments when a small-cap med-tech story stops being a promise and becomes a parade. Sight Sciences just delivered one of those quarters. Q2 2026 revenue hit $23.4M, up 20% year over year—the company's highest growth rate since 2023—and management responded by raising full-year guidance to $88M–$92M while simultaneously lowering adjusted operating expense guidance to $92M–$94M. The stock, already rising hard over the past 90 days (+139% on Sight Sciences itself), is now pricing in more than just a beat.
The interventional mindset gets paid
The heart of the narrative is Interventional Dry Eye (IDE). TearCare, the company's reimbursed procedure for evaporative dry eye, set a record: revenue nearly doubled sequentially to $2.7M, active accounts nearly doubled to 176, and utilization rose to 18 SmartLids per account. Even more telling, roughly two-thirds of SmartLids volume came from accounts that are also Interventional Glaucoma (IG) customers, and those accounts showed significantly higher utilization—a direct proof point for the company's "intersection of intervention" thesis.
Today, as we emerge—with IG back in growth, with IDE back in growth—believing we're flying a plane with 2 very strong engines right now, you couple that with excellence in operational discipline that we developed and fine-tuned over the past few years, we think we've struck a really good balance between growth and spend.
Paul Badawi's "two engines" metaphor is apt because glaucoma was the drag for two years. The company has now posted four consecutive quarters of year-over-year growth in IG, with utilization back to pre-LCD levels. In July, Aetna expanded coverage of OMNI and SION by roughly 25 million lives, completing access across all major national payers. Combined with the FDA 510(k) clearance of OMNI Ultra—featuring single-pass canaloplasty and TruSync Plus—the interventional mindset is now being backed by both reimbursement and product velocity.
Tariff refunds and the path to breakeven
One of the most remarkable reversals is on the bottom line. Gross margin jumped to 91%, aided by $1.4M of tariff refunds, but even ex-refunds the dry-eye segment's gross margin surged from 38% a year ago to 80%. That's not a one-off—it's a structural change in pricing and mix.
Cash burn is shrinking fast. Excluding a one-time $5.4M Alcon success fee and $1.6M in tariff-return cash, operating cash use was just $1.4M in the quarter, an 81% decline year over year. CFO Jim Rodberg was explicit on the goal:
“We ended the quarter with $79.8 million of cash and cash equivalents... Excluding these one-time items, cash used in the quarter was $1.4 million, down 81% from $7.3 million in the second quarter of 2025.” — Jim Rodberg, Chief Financial Officer · 2026-08-05
This cash discipline is visible in the fundamentals: effective net cash has fallen from a peak of $236M to about $45M, but management now insists breakeven requires no further equity raises. The efficiency gains of 2025—including a workforce reorganization—are now flowing through, and the company is reinvesting selectively in TearCare commercial build-out and market access.
A tale of two droughts
It's instructive to look back at what changed. Just a year ago, on the Q2 2025 call, CFO Alison Bauerlein (then in that role) admitted, "being now in August of the year of 2025 and having not yet had a win, we do acknowledge that we're slightly behind our expectations" in TearCare reimbursement. Today the tone is completely different. Ali Bauerlein, now COO, told analysts in Q2 2026:
“We were very happy to see that we had some of the Medicare Advantage plans in the quarter put fee schedules into their provider portals... impact in Q2 was very modest from those plans.” — Alison Bauerlein, Chief Operating Officer · 2026-08-05
The contrast is the whole story: last year it was hope, this year it's a funnel. The company added ~4.1M covered lives to reach 14.5M, and management explicitly stated that Q3 guidance of ~$3M for IDE assumes no further payer wins, meaning the incremental upside from additional fee schedules or coverage policies is option value.
Meanwhile, the stock's rally (recent 90D +139% per the tape) reflects a market that's beginning to value the TearCare option—not just the glaucoma base. As Paul said earlier this year on the Q1 call, "we are excited to be back in growth mode in Interventional Glaucoma" (component 4778593915599089747), and that growth is now compounding with a second, higher-velocity engine.
What's left to watch
Three things. First, the Alcon litigation: final judgment of $55M plus 10% royalties is on appeal, and no cash has been received—any resolution would be a step-change for the balance sheet. Second, the pace of additional MAC and commercial payer wins for TearCare—management is confident, but timing remains out of their control. Third, execution on the OMNI Ultra launch, which shifts from limited release now to full launch at AAO in Q4.
With revenue acceleration, gross margin expansion, and a clear path to cash flow breakeven, Sight Sciences is no longer a story about surviving headwinds. It's a story about two engines, finally both firing.